Intervention Protocol

Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathologic myopia

  1. Ying Zhu1,
  2. Ting Zhang1,
  3. Gezhi Xu1,*,
  4. Lijun Peng2

Editorial Group: Cochrane Eyes and Vision Group

Published Online: 15 JUN 2014

DOI: 10.1002/14651858.CD011160


How to Cite

Zhu Y, Zhang T, Xu G, Peng L. Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathologic myopia (Protocol). Cochrane Database of Systematic Reviews 2014, Issue 6. Art. No.: CD011160. DOI: 10.1002/14651858.CD011160.

Author Information

  1. 1

    Eye and Ear Nose Throat Hospital, Shanghai Medical School, Fudan University, Department of Ophthalmology, Shanghai, China

  2. 2

    Linyi People Hospital, Department of Gastroenterology, Linyi, Shandong, China

*Gezhi Xu, Department of Ophthalmology, Eye and Ear Nose Throat Hospital, Shanghai Medical School, Fudan University, No. 83, Fenyang Road, Shanghai, 200032, China. xugezhi@sohu.com.

Publication History

  1. Publication Status: New
  2. Published Online: 15 JUN 2014

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the effects of anti-vascular endothelial growth factor (anti-VEGF) therapy for choroidal neovascularisation (CNV), compared to other treatments, sham treatment or no treatment, in patients with pathologic myopia.